Connect with us

Medical Devices

LivaNova Reports First Quarter 2021 Results

Avatar

Published

on

LONDON–(BUSINESS WIRE)– LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2021.

For the first quarter of 2021, worldwide sales from continuing operations were $247.6 million, an increase of 2.1 percent on a reported basis and a decline of 0.4 percent on a constant-currency1 basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), first quarter 2021 diluted loss per share from continuing operations was $0.61. First quarter 2021 adjusted diluted earnings per share from continuing operations was $0.35.

“Epilepsy sales growth in the quarter reflects improving market dynamics, especially in the United States. The pace of vaccination efforts, along with patients’ and their caregivers’ willingness to seek treatment, is key to the continued recovery of the Epilepsy business,” said Damien McDonald, Chief Executive Officer of LivaNova. “We expect the recovery to continue from here and develop into more consistent sales and EPS growth in the second half of the year. We remain focused on delivering growth in our core, achieving pipeline milestones and executing on initiatives to improve profitability and cash generation.”

First Quarter 2021 Results

The following table summarizes worldwide sales for the first quarter of 2021 by business:

$ in millions

Three Months Ended March 31,

% Change

Constant-
Currency
% Change

Business / Product Line:

2021

2020

Cardiopulmonary

$108.7

$116.4

(6.6)

%

(10.2)

%

Heart Valves

21.5

25.2

(14.9)

%

(19.2)

%

Advanced Circulatory Support

13.0

10.5

23.8

%

23.6

%

Cardiovascular

143.2

152.1

(5.9)

%

(9.4)

%

Neuromodulation

103.7

89.7

15.7

%

14.7

%

Other

0.7

0.7

10.0

%

0.7

%

Total Net Sales

$247.6

$242.4

2.1

%

(0.4)

%

  • Note: Numbers may not add precisely due to rounding. Constant-currency percent change is a non-GAAP metric. For an explanation of this and other non-GAAP metrics used in this release, please see the section entitled “Use of Non-GAAP Financial Measures.” For reconciliations of certain non-GAAP metrics, please see the tables that accompany the press release.

All sales growth rates below reflect comparable, constant-currency growth. Constant-currency growth accounts for the impact from fluctuations in the various currencies in which the Company operates as compared to reported growth.

Cardiovascular

Cardiovascular sales, which include Cardiopulmonary, Heart Valves and Advanced Circulatory Support (ACS) products, were $143.2 million, representing a 9.4 percent decrease versus the first quarter of 2020.

Sales in Cardiopulmonary products were $108.7 million, representing a 10.2 percent decline versus the first quarter of 2020. The sales decline was primarily related to the impact of COVID-19 on cardiac surgery procedure volumes in the Europe and Rest of World regions, partially offset by capital equipment purchases.

Heart Valve sales were $21.5 million, a decrease of 19.2 percent compared to the first quarter of 2020.

ACS sales were $13.0 million in the quarter, an increase of 23.6 percent compared to the first quarter of 2020, due to the continued adoption of LifeSPARC™ in the U.S. and an increase in procedure volumes.

Neuromodulation

Neuromodulation sales were $103.7 million in the first quarter, representing a 14.7 percent increase versus the first quarter of 2020. This increase reflects improving market dynamics, particularly in the U.S. and Asia Pacific.

Financial Performance

On a U.S. GAAP basis, first quarter 2021 operating loss from continuing operations was $4.4 million. Adjusted operating income from continuing operations for the first quarter of 2021 was $31.6 million, an increase of 50.3 percent as compared to the first quarter of 2020, primarily driven by continued cost containment measures.

On a U.S. GAAP basis, first quarter 2021 effective tax rate was a negative 10.7 percent, as compared to 744.4 percent in the first quarter of 2020, which primarily reflects the discrete tax benefit of $41.3 million related to the Coronavirus Aid, Relief, and Economic Securities Act (CARES Act). The adjusted effective tax rate in the quarter was 10.8 percent, as compared to 8.2 percent in the first quarter of 2020, related to changes in the geographic income mix.

On a U.S. GAAP basis, first quarter 2021 diluted loss per share from continuing operations was $0.61. First quarter 2021 adjusted diluted earnings per share from continuing operations was $0.35, as compared to $0.33 per share in the first quarter of 2020.

2021 Guidance

LivaNova reaffirms its 2021 guidance, expecting worldwide net sales from continuing operations for the full year to grow between 8 and 13 percent on a constant-currency basis. Adjusted diluted earnings per share from continuing operations for 2021 are expected to be in the range of $1.40 to $1.90.

Webcast and Conference Call Instructions

The Company will host a live audio webcast for interested parties commencing at 12 p.m. London time (7 a.m. Eastern Time) on Wednesday, April 28 that will be accessible through the Investors section of the LivaNova website at www.livanova.com. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast. To listen to the conference call by telephone, dial 844-558-0159 (if dialing from within the U.S. or Canada) or 236-714-3182 (if dialing from outside the U.S. or Canada). The conference ID is 6493742. Within 24 hours of the webcast, a replay will be available under the “News / Events & Presentations” section of the Investors portion of the LivaNova website, where it will be archived and accessible for approximately 90 days.

1 Constant-currency percent change is a non-GAAP metric. For an explanation of this and other non-GAAP metrics used in this release, please see the section entitled “Use of Non-GAAP Financial Measures.” For reconciliations of certain non-GAAP metrics, please see the tables that accompany the press release.

About LivaNova

LivaNova PLC is a global medical technology and innovation company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through innovative medical technologies, delivering life-changing improvements for both the Head and Heart. Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.livanova.com.

Use of Non-GAAP Financial Measures

In this press release, management has disclosed financial measurements that present financial information not necessarily in accordance with GAAP. Company management uses these measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter and year to year on a regular basis and for benchmarking against other medical technology companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP.

Unless otherwise noted, all sales growth rates in this release reflect comparable, constant-currency growth. Management believes that referring to comparable, constant-currency growth is the most useful way to evaluate the sales performance of LivaNova and to compare the sales performance of current periods to prior periods on a consistent basis. Constant-currency growth, a non-GAAP financial measure, measures the change in sales between current and prior-year periods using average exchange rates in effect during the applicable prior-year period.

LivaNova calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For example, forward-looking net sales growth projections are estimated on a constant-currency basis and exclude the impact of foreign currency fluctuations. Forward-looking non-GAAP adjusted tax rate and adjusted diluted earnings per share guidance exclude other items such as, but not limited to, changes in fair value of contingent consideration arrangements, asset impairment charges and product remediation costs that would be included in comparable GAAP financial measures. The most directly comparable GAAP measure for constant-currency net sales, non-GAAP adjusted tax rate and adjusted diluted earnings per share are net sales, the effective tax rate and earnings per share, respectively. However, non-GAAP financial adjustments on a forward-looking basis are subject to uncertainty and variability as they are dependent on many factors, including but not limited to, the effect of foreign currency exchange fluctuations, impacts from potential acquisitions or divestitures, gains or losses on the potential sale of businesses or other assets, restructuring costs, merger and integration activities, changes in fair value of contingent consideration arrangements, product remediation costs, asset impairment charges, and the tax impact of the aforementioned items, tax law changes or other tax matters. Accordingly, reconciliations to the most directly comparable forward-looking GAAP financial measures are not available without unreasonable effort.

The Company also believes adjusted financial measures such as adjusted gross profit percentage; adjusted selling, general and administrative expense; adjusted research and development expense; adjusted other operating expenses; adjusted operating income from continuing operations; adjusted segment operating income; adjusted income tax expense; adjusted net income from continuing operations; and adjusted diluted earnings per share from continuing operations, are measures by which LivaNova generally uses to facilitate management review of the operational performance of the company, to serve as a basis for strategic planning and to assist in the design of compensation incentive plans. Furthermore, adjusted financial measures allow investors to evaluate the Company’s core performance for different periods on a more comparable and consistent basis, and with other entities in the medical technology industry by adjusting for items that are not related to the ongoing operations of the Company or incurred in the ordinary course of business.

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, LivaNova’s plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, our actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee,” or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based on estimates and assumptions that, while considered reasonable by LivaNova and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning achieving a stronger future, driving sustainable growth and value to our shareholders, projected net sales, adjusted diluted earnings per share, cash flow from operations, capital expenditures, and depreciation and amortization for 2021, advancing our growth, driving product launches and funding our equity investments, executing on our synergy targets and retaining our focus, energy and discipline as a company, and serving the needs of our customers and patients. Important factors that may cause actual results to differ include, but are not limited to: (i) the severity and duration of the COVID-19 pandemic and its impact on our business, financial condition and results of operations; (ii) reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services; (iii) unanticipated changes relating to competitive factors in the industries in which LivaNova operates; (iv) the ability to hire and retain key personnel; (v) the ability to attract new customers and retain existing customers in the manner anticipated; (vi) changes in legislation or governmental regulations affecting LivaNova; (vii) international, national or local economic, social or political conditions that could adversely affect LivaNova, its partners or its customers; (viii) conditions in the credit markets; (ix) business and other financial risks inherent to the industries in which LivaNova operates; (x) risks associated with assumptions made in connection with critical accounting estimates and legal proceedings; (xi) LivaNova’s international operations, which are subject to the risks of currency fluctuations and foreign exchange controls; (xii) the potential for international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs; (xiii) the inability of LivaNova to meet expectations regarding the timing, completion and accounting of tax treatments; (xiv) and organizational and governance structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company’s business, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova.

We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005232/en/

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.biospace.com/article/releases/livanova-reports-first-quarter-2021-results/?s=93

Medical Devices

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

Avatar

Published

on

DOORwaY-90 Study: Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the first patient has been enrolled in DOORwaY90, a study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma (HCC).

DOORwaY90, which stands for “Duration of Objective Response with Arterial Y-90,” is the first prospective, U.S.-based multicenter, open-label single arm study of its kind. The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash. Study enrollment is underway, with the first patient enrolled at Inland Imaging Associates and Providence Sacred Heart Medical Center in Spokane, Washington.

“We are thrilled to enroll the first patient in DOORwaY90,” said Dr. Mark A. Turco, Global Chief Medical Officer and EVP of Research and Development for Sirtex. “This clinical trial studying a heterogeneous population of patients with HCC using personalized dosimetry planning has the potential to advance the treatment of HCC patients worldwide. We are deeply thankful to every clinical investigator and patient who will be part of this groundbreaking journey.”

With a planned enrollment of 100 subjects across 15 sites both academic and non-academic, DOORwaY90 is enrolling patients with Barcelona Clinic Liver Cancer (BCLC) Stage A, B1 and B2 who are not eligible for resection or ablation at the time of study entry. The study is unique because it is the first FDA-approved U.S.-based prospective trial to utilize and delineate personalized dosimetry treatment planning and to define actionable post-treatment dosimetric verification for endpoint assessment.

“It’s important for physicians to have confidence that their planned Y-90 dose is being delivered in the right amount and to the right place,” said Dr. Douglas Murrey, Vascular and Interventional Radiologist at Inland Imaging Associates and Providence Sacred Heart Medical Center in Spokane, Washington. “The personalized dosimetry component of the DOORwaY90 study will provide meaningful insights to advance our practice and patient outcomes.”

HCC is often diagnosed when potentially curative resection or transplantation is not feasible. SIRT has the potential to deliver a lethal dose of radiation to hepatic tumors, while sparing surrounding healthy liver tissue. In countries outside the U.S., SIRT has been successfully used to bridge patients to transplantation or downstage HCC to within transplantation criteria or resection.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/doorway-90-study/

Continue Reading

Medical Devices

Global Surgical Lasers Market to Reach $10.1 Billion by 2027

Avatar

Published

on

Global Surgical Lasers Market Industry Report – https://www.reportlinker.com/p06033049/?utm_source=GNW

1 Billion by 2027, growing at a CAGR of 9.7% over the analysis period 2020-2027. Solid-State Laser Systems, one of the segments analyzed in the report, is projected to record a 9.2% CAGR and reach US$3.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gas Laser Systems segment is readjusted to a revised 10.6% CAGR for the next 7-year period.

– The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 12.8% CAGR
– The Surgical Lasers market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2027 trailing a CAGR of 12.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 8.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.
– Diode Laser Systems Segment to Record 9.7% CAGR
– In the global Diode Laser Systems segment, USA, Canada, Japan, China and Europe will drive the 9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$833.8 Million in the year 2020 will reach a projected size of US$1.5 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027, while Latin America will expand at a 11.1% CAGR through the analysis period.

Select Competitors (Total 42 Featured) –

  • Abbott Laboratories, Inc.
  • Alma lasers
  • Biolitec AG
  • Bison Medical Co. Ltd
  • Boston Scientific Corporation
  • Cynosure Inc.
  • Lumenis
  • Sharp light Technology
  • Spectranetics Corporation
  • Syneron Medical Ltd

Read the full report: https://www.reportlinker.com/p06033049/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Surgical Lasers by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Surgical Lasers by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Surgical Lasers by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Solid-State Laser
Systems by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Solid-State Laser Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Solid-State Laser
Systems by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 7: World Current & Future Analysis for Gas Laser Systems
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Gas Laser Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Gas Laser Systems by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Diode Laser
Systems by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Diode Laser Systems by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Diode Laser Systems by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Types by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Types by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Other Types by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Ambulatory
Surgical Centers by Geographic Region – USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets – Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Ambulatory Surgical Centers
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Ambulatory Surgical
Centers by Geographic Region – Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 19: World Current & Future Analysis for Hospitals by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Hospitals by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Hospitals by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Specialty Clinics
by Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Specialty Clinics by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Specialty Clinics by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Aesthetic by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Aesthetic by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Aesthetic by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Surgical by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Surgical by Geographic
Region – USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets – Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Surgical by Geographic
Region – Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Other
Applications by Geographic Region – USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Other Applications by
Geographic Region – USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets –
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Other Applications by
Geographic Region – Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 34: USA Current & Future Analysis for Surgical Lasers by
Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 36: USA 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 37: USA Current & Future Analysis for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

CANADA
Table 43: Canada Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 45: Canada 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 46: Canada Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

JAPAN
Table 52: Japan Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 54: Japan 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 55: Japan Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

CHINA
Table 61: China Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 63: China 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 64: China Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 67: China Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

EUROPE
Table 70: Europe Current & Future Analysis for Surgical Lasers
by Geographic Region – France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 and %
CAGR

Table 71: Europe Historic Review for Surgical Lasers by
Geographic Region – France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets – Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Surgical Lasers by
Geographic Region – Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 75: Europe 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

FRANCE
Table 82: France Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 84: France 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 85: France Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 88: France Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

GERMANY
Table 91: Germany Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: Germany Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 93: Germany 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 94: Germany Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 95: Germany Historic Review for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 98: Germany Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

ITALY
Table 100: Italy Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 101: Italy Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 102: Italy 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 103: Italy Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 104: Italy Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 105: Italy 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: Italy Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 108: Italy 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

UNITED KINGDOM
Table 109: UK Current & Future Analysis for Surgical Lasers by
Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 110: UK Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 111: UK 15-Year Perspective for Surgical Lasers by Type –
Percentage Breakdown of Value Sales for Solid-State Laser
Systems, Gas Laser Systems, Diode Laser Systems and Other Types
for the Years 2012, 2020 & 2027

Table 112: UK Current & Future Analysis for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics – Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 113: UK Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 114: UK 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 116: UK Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

SPAIN
Table 118: Spain Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 119: Spain Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 120: Spain 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 121: Spain Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 122: Spain Historic Review for Surgical Lasers by End-Use –
Ambulatory Surgical Centers, Hospitals and Specialty Clinics
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 123: Spain 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 124: Spain Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 125: Spain Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 126: Spain 15-Year Perspective for Surgical Lasers by
Application – Percentage Breakdown of Value Sales for
Aesthetic, Surgical and Other Applications for the Years 2012,
2020 & 2027

RUSSIA
Table 127: Russia Current & Future Analysis for Surgical Lasers
by Type – Solid-State Laser Systems, Gas Laser Systems, Diode
Laser Systems and Other Types – Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 128: Russia Historic Review for Surgical Lasers by Type –
Solid-State Laser Systems, Gas Laser Systems, Diode Laser
Systems and Other Types Markets – Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019 and %
CAGR

Table 129: Russia 15-Year Perspective for Surgical Lasers by
Type – Percentage Breakdown of Value Sales for Solid-State
Laser Systems, Gas Laser Systems, Diode Laser Systems and Other
Types for the Years 2012, 2020 & 2027

Table 130: Russia Current & Future Analysis for Surgical Lasers
by End-Use – Ambulatory Surgical Centers, Hospitals and
Specialty Clinics – Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 131: Russia Historic Review for Surgical Lasers by
End-Use – Ambulatory Surgical Centers, Hospitals and Specialty
Clinics Markets – Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 132: Russia 15-Year Perspective for Surgical Lasers by
End-Use – Percentage Breakdown of Value Sales for Ambulatory
Surgical Centers, Hospitals and Specialty Clinics for the Years
2012, 2020 & 2027

Table 133: Russia Current & Future Analysis for Surgical Lasers
by Application – Aesthetic, Surgical and Other Applications –
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 134: Russia Historic Review for Surgical Lasers by
Application – Aesthetic, Surgical and Other Applications
Markets – Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 135: Russia 15-Year Perspective for Surgical Lasers by

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/global-surgical-lasers-market/

Continue Reading

Medical Devices

Carestream Health Advances X-ray Image Quality with Smart Noise Cancellation

Avatar

Published

on

Carestream Health has released Smart Noise Cancellation (SNC), a groundbreaking artificial intelligence (AI)-based technology that greatly improves image quality—producing images that are significantly clearer than with standard processing.

SNC has received FDA 510(k) Clearance and is available as an optional feature with Carestream’s ImageView Software powered by Eclipse—the intelligent image-processing engine behind the company’s innovative imaging software—on DRX-Evolution and DRX-Evolution Plus systems.

“Carestream is a leader in using AI for noise cancellation with X-ray images. Our team of imaging scientists has been able to separate image noise from sharpness and contrast using AI-based algorithms that result in remarkable image quality,” said Jill Hamman, Worldwide Marketing Manager, Global X-ray Solutions at Carestream. “This technology provides improved anatomical clarity, preservation of fine detail and better contrast-to-noise ratio for images acquired at a broad range of exposures, which can help improve diagnostic confidence and alleviate physician fatigue. It also enables radiology professionals to better optimize radiation dose.” Optimizing radiation dose is especially important with neonatal and pediatric diagnostic imaging, where imaging at the lowest possible dose is crucial for young patients.

Separating noise from an image has been a challenge for medical imaging scientists. Traditional noise reduction introduces blurring, which degrades image sharpness and might remove important anatomical information. Conversely, the more an image is sharpened, the more noise may be enhanced. Noise is often an undesirable by-product of image capture and can obscure critical anatomical data. Carestream’s SNC is able to isolate noise to produce images that are significantly clearer than with standard processing.

As the preferred level of noise on X-ray images is subjective—for example, some radiologists expect to see a certain degree of noise in images, which assures them that the patient was not overexposed—Carestream enables imaging professionals to adjust the amount of noise cancellation and exposure to meet their desired image quality.

Carestream Health notes objective testing demonstrated that SNC processing enables a 2x–4x noise reduction in flat image areas, preserves high frequency sharpness and improves contrast detail. Additionally, a blind Clinical Reader Study using board-certified radiologists found that 89.5 percent of all study ratings showed a slight to strong preference for SNC-processed images. Sixty-four percent of the diagnostic quality ratings improved—based on the RadLex rating scale—and 56 percent of these ratings improved from “limited” or “diagnostic” to “exemplary.”

Carestream Health notes when combined with SmartGrid software, Smart Noise Cancellation software promises benefits in gridless imaging where the removal of scatter typically leads to an increase in noise appearance.

“At Carestream, improving image quality is a top priority for our R&D team,” Ms. Hamman said. “Smart Noise Cancellation provides the ability to consistently deliver high-quality diagnostic images for healthcare providers and their patients.”

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/carestream-health-smart-noise-cancellation/

Continue Reading

Medical Devices

Vector Remote Care: Study Finds Remote Cardiac Monitoring Programs Significantly More Successful When Patients, Not Devices, Are Primary Focus

Avatar

Published

on

Vector Remote Care today announced the results of a survey on the adoption of remote cardiac monitoring solutions and their impact on managing heart disease in the U.S.

The findings reveal that remote cardiac monitoring (RCM) programs that focus on just remote device data management are missing out on both clinical and financial benefits. In comparison, cardiology practices taking a patient-centric approach focused on data and patient compliance, report improved clinical and financial outcomes.

The survey of over 110 respondents with various roles within a cardiology practice shows nearly 75 percent of respondents believe improving patient outcomes is the first or second priority for their monitoring program.

Nevertheless, narrowing the scope to physician respondents, 43 percent revealed that only 20 percent or less of their heart disease patients are connected (and result in billable reports), which indicates a large margin of missed opportunities for improved clinical and financial outcomes. Despite less-than-optimal connection rates, a strong majority of total respondents—68.75 percent— rate their program as good or excellent.

According to Kristin Stitt, DNP, APRN, Chief Clinical Officer at Vector, “These numbers are not surprising, as RCM is still relatively new. Strong satisfaction with a program that has low connection rates indicates that many practices focus on getting the devices up and running, but are not fully aware of what is possible when you design your program around patient care.”

While 93.52 percent of respondents are doing remote monitoring for rhythm management, about one-third of those practices have less than 60 percent of their patients regularly connected. In addition, fewer than 68 percent of respondents are monitoring for heart failure, and fewer than 19 percent are monitoring for hypertension.

Programs with 80-100 percent of their patients connected are most successful at gathering the revenue needed to cover program costs. Practices with less than 60 percent of patients routinely connected for billable reports clearly see covering costs as a significant challenge.

Electrophysiologist Christopher Porterfield, MD, states, “There are hundreds to thousands of stories where remote monitoring has made it easier to care for patients and, in many cases, to save lives.” Dr. Porterfield assisted with survey development and analysis of the responses.

Additional findings show practices struggle to keep patients engaged in their care, placing a strain on staff and making it impossible for clinical and financial benefits to be fully realized. All respondents view keeping patients connected, reviewing alerts, and preparing reports as their biggest challenges, but practices’ staff doing the monitoring are the most burdened.

Respondents partnering with a third-party vendor cite improved satisfaction in being able to offload time-consuming administrative work. Third party success in enrolling patients, keeping them connected, and collecting appropriate revenue is likely due to a combination of clear goals, streamlined workflows, technology, and support services that ease burdens listed above.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/vector-remote-care-study-finds-remote-cardiac-monitoring-programs-significantly-more-successful-when-patients-not-devices-are-primary-focus/

Continue Reading
Aviation5 days ago

What Happened To Lufthansa’s Boeing 707 Aircraft?

Blockchain5 days ago

Launch of Crypto Trading Team by Goldman Sachs

Aviation4 days ago

JetBlue Hits Back At Eastern Airlines On Ecuador Flights

Aviation5 days ago

United Airlines Uses The Crisis To Diversify Latin American Network

Cyber Security4 days ago

Cybersecurity Degrees in Massachusetts — Your Guide to Choosing a School

Blockchain5 days ago

Miten tekoälyä käytetään videopeleissä ja mitä tulevaisuudessa on odotettavissa

Blockchain5 days ago

DOGE Co-founder Reveals the Reasons Behind its Price Rise

Blockchain4 days ago

“Privacy is a ‘Privilege’ that Users Ought to Cherish”: Elena Nadoliksi

Cyber Security5 days ago

U.S. and the U.K. Published Attack on IT Management Company SolarWinds

AI1 day ago

Build a cognitive search and a health knowledge graph using AWS AI services

Fintech5 days ago

The Spanish fintech Pecunpay strengthens its position as a leader in the issuance of corporate programs

Blockchain News5 days ago

Nasdaq-Listed Metromile Backs Bitcoin for its Insurance Products

Blockchain5 days ago

Crypto.com Now Enabling Cosmos’ Inter-Blockchain Communication Functionality for Cross-Chain Transfers

Cyber Security4 days ago

Cybersecurity Degrees in Texas — Your Guide to Choosing a School

SaaS5 days ago

Blockchain24 hours ago

Meme Coins Craze Attracting Money Behind Fall of Bitcoin

Cleantech5 days ago

What We Know About Tesla’s “Bobcat Project”

Energy2 days ago

ONE Gas to Participate in American Gas Association Financial Forum

Aviation5 days ago

Ryanair Goes Full Steam Ahead On Portugal Capacity Expansion

Blockchain4 days ago

Opimas estimates that over US$190 billion worth of Bitcoin is currently at risk due to subpar safekeeping

Trending